Table 1: Summary of pharmacokinetic parameters of empagliflozin

Parameter

Empagliflozin

Empagliflozin+glimepiride

AUCτ,ss, nmol·h/L

9370 (15.4)

8910 (14.2)

Cmax,ss, nmol/L

1350 (23.0)

1280 (14.1)

tmax,ss, hours*

1.5 (1.0–4.0)

1.5 (1.0–2.5)

t½,ss, hours

8.20 (10.7)

12.8 (59.2)

fe0-24,ss, %

20.0 (15.7)

20.5 (14.0)

CLR,0-24,ss, mL/min

40.3 (22.6)

43.5 (21.6)

N=16. Data are mean (%CV) unless otherwise stated.

*Median (range).
AUC
τ,ss, area under concentration-time curve of empagliflozin in plasma at steady state;Cmax,ss, maximum measured concentration of empagliflozin in plasma at steady state; tmax,ss, time from last dosing to maximum concentration of empagliflozin in plasma at steady state; t1/2,ss, terminal half-life of empagliflozin in plasma at steady state; fe0-24,ss, fraction of empagliflozin excreted unchanged in urine at steady state over 24 hours after dosing; CLR,0-24,ss renal clearance of empagliflozin at steady state over 24 hours after dosing.

Macha et al.Journal of Diabetes Research and Clinical Metabolism  2012 1:14DOI : 10.7243/2050-0866-1-14